attention-deficit/hyperactivity disorder (aDhD), the most common pediatric neurobehavioral disorder, frequently presents with coexisting reading disorders (rDs). Despite this, it is unclear whether medication improves symptoms and function in children with comorbid aDhD and rD. We present a systematic review of studies investigating the effects of aDhD medications on aDhD symptoms, academic outcomes, and neuropsychological measures in this important group.
frequently compounded by co-occurring disorders. A recent nationally representative study reported that two-thirds of children with ADHD have a coexisting developmental-behavioral condition, of which the most common was learning disorder (LD). 5 Of particular importance are comorbid reading disorders (RDs), as prior studies suggest that 25-48% of children with ADHD have coexisting RDs. 6 The high degree of intersection between ADHD and RD (ADHD + RD) is not surprising given evidence of their common genetic and neuropsychological underpinnings. Twin studies suggest that shared genetic influences account for a portion of the comorbidity between ADHD and RDs, [7] [8] [9] with additional studies pinpointing specific genetic variants that may be linked to ADHD + RD. 10, 11 Furthermore, similar neuropsychological deficits in ADHD and RD highlight the possibility of overlapping neural factors. For example, working memory deficits have been reported in both ADHD and RD. [12] [13] [14] In addition, processing speed issues have been observed in children with ADHD as well as those with RDs. [15] [16] [17] [18] Rapid automatized naming deficits, which have long been recognized in children with RD, 19 have also been documented in children with ADHD only. 20, 21 Although there is abundant evidence of the overlap between ADHD and RD in epidemiologic, genetic, and neuropsychological investigations, the degree of benefit children with coexisting ADHD + RD receive from ADHD-specific medications is less clear. 22, 23 Among parents of children with ADHD, it is known that parental concern about academic performance, which one would expect to be intensified in cases of coexisting ADHD + RD, is linked to medication initiation. 24 Therefore, an increased understanding of whether ADHD medications improve symptoms and functioning for this prevalent group has much salience in the clinical setting. Indeed, studies of medication efficacy in children with ADHD and other neurobehavioral comorbidities have reported differential effects compared to what is seen with ADHD only: methylphenidate (MPH), the most commonly prescribed ADHD medication, has lower response rates in children with ADHD and coexisting autism spectrum disorders compared to typically developing children with ADHD. [25] [26] [27] [28] Of note, some clinicians have expressed concern that children with coexisting ADHD and RD may not experience as much improvement in ADHD symptoms with medications as children with ADHD only, and as a result may be less likely to prescribe medication to this group. 29 Effects of ADHD medications on learning in children with ADHD + RD are another important consideration. There is evidence that children with ADHD but no comorbid LD demonstrate improvement on some academic skills with medication, 30 but the affected skills are limited and these gains may not generalize to those with RD. If an RD in a child with ADHD represents a distinct biologically based condition, it is possible that medical treatment that reduces primary ADHD symptoms may not lead to corresponding improvement in learning. Therefore, we undertook a systematic review of the literature to evaluate the evidence regarding effects of US Food and Drug Administration-approved ADHD medications (e.g., psychostimulants, atomoxetine, guanfacine, and clonidine) in children with coexisting ADHD + RD on the following domains: (1) ADHD symptoms; (2) academic outcomes; and (3) neuropsychological measures. Due to the sparsity of literature available on this topic, in addition to reviewing double-blind studies comparing medication effects to placebo (PB), we have also included openlabel studies that evaluated medication effects by comparing participants' performance on premeasures and postmeasures.
SEARCH STRATEGY AND EVIDENCE GRADING PROCEDURES
This systematic review followed reporting guidelines set out in the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 31 statement. We searched PubMed, 32 PsycINFO, 33 Cochrane Database of Systematic Reviews, 34 and the Education Resources Information Center (ERIC) 35 databases for Englishlanguage articles published in peer-reviewed journals after 1980 using combinations of the following terms: "ADHD" (encompassing both the acronym and the full term), "learning disabilities," "learning disorders," "treatment," "intervention," "therapy," and "medication." Additional searches were conducted using relevant drug names (MPH, amphetamine, dextroamphetamine, atomoxetine, guanfacine, and clonidine). We hand-searched the reference lists of retrieved articles, including review articles and epidemiological studies, to identify any additional relevant references. Searches were conducted independently by two researchers (T.F. and N.E.) in order to ensure all relevant records were identified.
The authors reviewed titles, abstracts, and full text to determine relevance for inclusion. We included articles that met the following criteria: (1) clinical trial; (2) children were identified as having both RD and ADHD (identified using the Diagnostic and Statistical Manual of Mental Disorders criteria appropriate for the time at which the study was conducted); (3) participants received treatment with an US Food and Drug Administrationapproved medication for ADHD, such as MPH or atomoxetine; and (4) treatment efficacy was evaluated using at least one valid outcome measure for ADHD symptoms, academic achievement/ skills, or neuropsychological functioning. We excluded studies that enrolled fewer than 10 children with ADHD-RD, or had subjects who also had a comorbid intellectual disability, specific genetic syndrome, or autism spectrum disorder, or who were over 18 years of age.
Two authors (T.F., J.F., W.B., or E.C.) independently abstracted data from each article using the McMaster Effective Public Health Practice Project Quality Assessment Tool for quantitative studies. 36 This tool was annotated for crossover studies using criteria proposed by Ding et al. 37 and Mills et al. 38 Discrepancies were resolved through consensus. We used the Oxford Centre for Evidence-Based Medicine criteria 39 to rate each study and assess the overall strength of the body of evidence for treatment recommendations.
SEARCH RETRIEVAL RESULTS
We identified 443 independent records of potential relevance. After applying inclusion and exclusion criteria, we identified 14 treatment studies to be included in this review ( Figure 1) . Studies focused on the effects of stimulant medications or atomoxetine in children with ADHD and coexisting RD, as we did not identify any studies that focused on clonidine or guanfacine effects in this clinical group. Two studies 40,41 also included some children who had ADHD and comorbid mathematic disorders (MDs) or ADHD with both comorbid RDs and MDs.
STIMULANT EFFECTS ON ADHD SYMPTOMS IN CHILDREN WITH ADHD + RD
We identified five controlled clinical trials (CCTs) and one cohort analytic open-label study that investigated effects of stimulant medications on ADHD symptoms in children with ADHD + RD ( Table 1) , with four studies focusing exclusively on children with coexisting RDs [42] [43] [44] [45] and two studies including children with documented coexisting MDs as well as RD. 40, 41 All studies focused on effects of MPH treatment, except for a non-blinded controlled trial by Tamm et al. 43 Tamm et al. 43 used a protocol providing ADHD behavioral parent training as well as medication treatment with varying agents depending on participant response, yielding a sample treated with MPH (46%), amphetamine and/ or dextroamphetamine (42%), atomoxetine (4%), and guanfacine (6%). Given that most children in the Tamm et al. 43 study were treated with psychostimulants, it will be discussed in this section.
Blinded direct observations of ADHD-related behaviors
In a double-blind placebo-controlled (DBPC) crossover trial of children with ADHD + LD (RD and/or MD), MPH led to improvements in directly observed ADHD-related behaviors. 40 In this study, Williamson et al. 40 found that children with ADHD + LD treated with MPH were more attentive (Swanson, Kotkin, Alger, M-Flynn, and Pelham (SKAMP) attention subscale least square mean scores (SE) on MPH = 6.5 (0.68) vs. on PB = 10.7 (0.68); P < 0.0001) and better behaved (SKAMP deportment subscale least square mean scores (SE) on MPH = 3.6 (0.70) vs. on PB = 8.2 (0.71); P < 0.0001).
Parent-reported ADHD symptoms
Five studies compared parent ratings of ADHD symptoms on stimulants to baseline or placebo condition ratings in children with ADHD + RD. Kupietz et al. 45 conducted a DBPC trial and found improvements in parent hyperactivity-impulsivity ratings with MPH (mean parent ratings (adjusted for baseline score) for the PB, MPH = 0.3 mg/kg, MPH = 0.5 mg/kg, and MPH = 0.7 mg/kg groups were 2.51, 2.39, 2.36, and 1.8, respectively; main effect of dose F 3,40 = 4.28, P < 0.01). However, another DBPC trial of children with ADHD + RD by Tannock et al. 42 did not observe beneficial effects of MPH on parentreported inattention or hyperactivity-impulsivity. A non-blinded CCT by Tamm et al. 43 documented large beneficial effects of ADHD treatment on parent ADHD symptom ratings (d = 1.1 and d = 0.8 for ratings of inattention and hyperactivity, respectively). A CCT (not blinded for ADHD symptom assessment) by Williamson et al. 40 of children with ADHD and coexisting RD and/or MD found that MPH significantly improved (all P values < 0.001) caregiver ratings of child inattention (baseline score (SD) = 20.8 (4.2); final visit score (SD) = 6.0 (3.6)); hyperactivity/impulsivity (baseline score (SD) = 16.1 (6.4); final visit score (SD) = 3.4 (2.9 )); and ADHD total symptoms score (baseline score (SD) = 36.9 (8.4); final visit score (SD) = 9.4 (5.7)). An additional non-blinded cohort analytic study by Dykman et al. 44 found that MPH had significant positive effects on children with ADHD + RD (P values < 0.001), with large effect sizes for mean change in parent-rated inattention (d = 1.57) and hyperactivity/impulsivity (d = 1.14).
Teacher-reported ADHD symptoms
Five studies compared teacher ratings of ADHD symptoms on stimulants to baseline or PB condition ratings in children with ADHD + RD. The DBPC trial by Kupietz et al. 45 found a significant main effect of dose on teacher ADHD symptom ratings (F 3,35 = 11.73, P < 0.01, mean teacher ratings (adjusted for baseline score) for the PB, MPH 0.3 mg/kg, MPH 0.5 mg/kg, and MPH 0.7 mg/kg groups were 2.43, 1.93, 1.85, and 1.62, respectively), indicating a trend for greater improvement with increasing MPH dose, which did not vary by symptom domain (i.e., no difference in magnitude of improvements seen for the inattention vs. hyperactivity factors). Intention-to-treat analyses in a DBPC trial of children with ADHD + RD by Tannock et al. 42 also showed significant albeit modestly sized beneficial effects of MPH on teacher-rated hyperactivity/impulsivity (MPH group adjusted t score mean = 59.6 vs. PB group adjusted t score mean = 68.7, r = 0.34, P = 0.04). In Figure 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram of the article selection process. ADHD, attention-deficit/hyperactivity disorder; ADHD + LD, coexisting attention-deficit/hyperactivity disorder and learning disorder; ASD, autism spectrum disorder; LD, learning disorder; RD, reading disorder. PubMed -107  PsycINFO -266  Cochrane Database of Systematic Reviews -61  Education Resources Information Center - 
Records identified through database searching

Full-text articles excluded
Participants did not meet ADHD diagnostic criteria -2 <10 participants with ADHD+RD -2 Testing not done while children were on medication -1 No analysis of impact of ADHD+RD -2 RD not defined using specific criteria -1 Participants had other LD but not RD -1
Number of studies included in qualitative analysis
(N = 14) Described as randomized by authors but classified as a CCT rather than a randomized control trial due to lack of detail regarding randomization procedures.
c Quality rating downgraded from 1b due to exclusion of children with history of poor response to stimulants. contrast, Tannock et al. 42 did not observe significant MPH effects for teacher inattention ratings in intention-to-treat analyses, although additional "as treated" analyses did show improvement with MPH on both teacher-rated inattention and hyperactivity/impulsivity (both P values < 0.01). A nonblinded CCT by Tamm et al. 33 found large effects of ADHD treatment on teacher ADHD symptoms ratings for children with ADHD + RD (d = 1.4 and d = 1.0 for improvements in inattention and hyperactivity/impulsivity ratings respectively). A CCT by Williamson et al. 40 of children with ADHD and coexisting RD and/or MD (not blinded for ADHD symptom assessment) observed that MPH significantly improved teacher-reported child ADHD total symptom scores (baseline score (SD) = 27.8 (12.1); final visit score (SD) = 10.9 (11.5), P < 0.001), with effects on inattention and hyperactivity/impulsivity not reported separately. An additional nonblinded cohort analytic study by Dykman et al. 44 found that MPH had significant positive effects (P values < 0.001) on children with ADHD + RD, with large effect sizes for mean change in teacher-rated inattention (d = 2.19) and hyperactivity/impulsivity (d = 1.59).
Frequency of positive response to MPH
Two investigations assessed stimulant medication response rates in children with ADHD and RD and/or MD. 40, 41 The DBPC crossover study by Grizenko et al. 41 found that, according to a consensus clinical response rating developed by the research team, the proportion of children with ADHD + LD who responded to MPH was significantly lower than the proportion of MPH responders with ADHD only (55% vs. 75%, P = 0.03). However, further analyses showed that the difference was mainly due to poor MPH response in children with ADHD + MD (P = 0.03), whereas children with ADHD + RD did not show a differential MPH response compared to those without coexisting RD (P = 0.33). The MPH response rates were 67% for those with ADHD + RD only, 55% for those with both ADHD + both RD and MD, and 37% for those with ADHD + MD only. The CCT by Williamson et al., 40 for which clinician ratings were not blinded, found that 79% of participants with ADHD + LD (both RD and MD included but not analyzed separately) achieved ratings by nonblinded clinicians of "much improved" or "very much improved" with MPH treatment.
Summary of findings
One DBPC trial and the three nonblinded trials observed significant benefits of stimulants on parent-reported ADHD symptom ratings in ADHD + RD samples, whereas one DBPC trial did not. All identified trials (two DBPC and three nonblinded) documented improvements in teacher-ratings of ADHD symptoms with stimulant treatment in children with ADHD + RD. There is evidence from one study that stimulant medication treatment in children with ADHD + RD may improve child attention and behavior when assessed via blinded direct observations. The available literature also suggests that MPH response rates may be lower in ADHD + MD but not ADHD + RD compared to those with ADHD only, although this conclusion is based on a single study assessing response rates in ADHD + RD separately from ADHD + MD.
STIMULANT EFFECTS ON ACADEMIC OUTCOMES IN CHILDREN WITH ADHD + RD
We found five CCTs and two cohort analytic open-label study that investigated stimulant medication effects on academic outcomes in children with ADHD + RD ( Table 2) , with most studies focusing on MPH effects on reading.
Reading
Five CCTs [40] [41] [42] [43] 46 and one open-label cohort analytic study 44 investigated effects of stimulant medications on reading outcomes in children with ADHD + RD. A variety of reading-related constructs were evaluated, including decoding, phonological awareness, reading fluency, reading comprehension, and spelling.
meeting diagnostic criteria for rD
An analysis of data from the landmark Multimodal Treatment Assessment of ADHD randomized controlled trial by Hechtman et al. 46 found that among children meeting criteria for ADHD + RD at baseline, there was a borderline significant decrease in likelihood of meeting criteria for RD at the end of the 14-month trial in the rigorously titrated MPH group compared to the community care group (odds ratio = 2.03, 95% confidence interval = 0.98-4.20, P = 0.055) and in the combined MPH and behavior treatment group compared to the community care group (odds ratio = 3.33, 95% confidence interval = 0.92-12.11, P = 0.067), although the MPH and combined treatment groups showed no advantage over the behavior treatment-only group on this outcome.
Word reading/decoding and phonological awareness
Effects of MPH on decoding and phonological awareness skills have not been consistent in trials of children with ADHD + RD. In a DBPC trial of children with ADHD + RD, Bental and Tirosh 47 found significant effects of MPH treatment on word decoding and pseudoword decoding accuracy (P = 0.03 and P = 0.04, respectively, on Nitzan Diagnostic Battery (NDB) measures) but not on NDB phonemic synthesis or phonemic deletion subtests. In their DBPC trial, Tannock et al. 42 found significant effects of MPH in ADHD + RD on speech-sound discrimination skills (F(1, 58) = 7.17, P = 0.003, on the Goldman-FristoeWoodcock Sound Analysis subtest), but not word attack or word identification (Woodcock Reading Mastery Tests-Revised (WRMT-R) subtests, Keyword Test, and Test of Transfer). In a cohort analytic study, Keulers et al. 48 found that MPH led to significantly greater improvements in word decoding (assessed on the One Minute Test and Three Minutes Test) and nonword decoding skills (assessed on the Klepel Test) for children with ADHD + RD compared to the ADHD-only group. However, in a CCT of children with ADHD + RD by Tamm et al., 43 word reading and pseudoword decoding skills (assessed using the Wechsler Individual Achievement Test-Third Edition) improved more with a reading skills intervention than with stimulant medication treatment. Two DBPC trials evaluated effects of MPH on reading comprehension in ADHD + RD. In a sample of children with ADHD + RD, Tannock et al. 42 found no significant effects of MPH on reading comprehension skills on the WRMT-R. In a sample including children with ADHD + RD and/or ADHD + MD, Williamson et al. 40 found borderline significant benefits of MPH on reading comprehension (Gray Silent Reading Test mean score (SD) = 83.6 (14.9) with MPH vs. 78.5 (22.3) with PB, P = 0.099).
Spelling
The DBPC trial of children with ADHD + RD by Bental and Tirosh 47 did not find significant effects of MPH on spelling accuracy (assessed by copying sentences from the Test of Hand Writing Quality).
Mathematics
We identified two DBPC trials 40, 42 and one cohort analytic open-label trial 44 that investigated effects of MPH on math outcomes in children with ADHD + RD. In a DBPC crossover trial of children with ADHD and coexisting RD and/or MD, Williamson et al. 40 found significant benefits of MPH on math computation skills (Permanent Product Math Test arithmetic problems correct least squares mean score (SD) = 95.7 (3.2) with MPH vs. 76.7 (3.2) with PB, P < 0.0001). Tannock et al. 42 also found that MPH had significant beneficial effects on arithmetic skills F 1,55 = 7.79, P = 0.01, on the Wide Range Achievement Test-Revised) in a DBPC trial of children with ADHD + RD. Similarly, an open-label study of children with ADHD + RD by Dykman et al. 44 found beneficial effects of MPH on arithmetic performance (20-minute task consisting of addition and subtraction problems, d = 0.26-0.34, P < 0.01).
Handwriting
In a DBPC crossover trial of children with ADHD and coexisting RD and/or MD, Williamson et al. 40 found significant benefits of MPH on handwriting (Test of Handwriting Skills-Revised mean score (SD) = 90.0 (21.2) with MPH vs. 85.7 (21.1) with PB, P = 0.0001).
Summary of findings
Effects of stimulant medications on reading skills have been mixed in prior studies of children with ADHD + RD. Although only three studies have assessed effects of MPH on math performance in children with ADHD + RD, they all documented significant improvement in computation performance with treatment. The single available trial evaluating MPH effects on handwriting in children with ADHD + RD showed positive treatment effects.
STIMULANT EFFECTS ON NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH ADHD + RD
We identified three DBPC crossover trials 40, 45, 47 and one openlabel cohort analytic study 48 that investigated effects of MPH on neuropsychological outcomes in children with ADHD + RD ( Table 2) .
Paired-associate learning
In their DBPC trial of children with ADHD + RD, Kupietz et al. 45 found that MPH reduced errors in paired-associate learning at higher Described as randomized by authors but classified as a CCT rather than a randomized control trial due to lack of detail regarding randomization procedures.
c Quality rating downgraded from 1b due to exclusion of children with history of poor response to stimulants. doses (0.5 mg/kg and 0.7 mg/kg) at the end but not beginning of the trial (end of trial mean errors (adjusted for baseline) on PB, MPH 0.3 mg/kg, MPH 0.5 mg/kg, and MPH 0.7 mg/kg 2.6, 2.8, 1.8, and 1.0, respectively; dose*time interaction F 3,41 = 3.34, P < 0.05).
Rapid automatized naming skills
In a DBPC trial that evaluated effects of MPH on children with ADHD + RD, Bental and Tirosh 47 reported beneficial effects of active treatment compared to PB on the Rapid Automatized Naming test of digits (t = −0.214, P = 0.04).
Reaction time variability
In a DBPC crossover trial of children with ADHD and coexisting RD and/or MD, Williamson et al. 40 found significant benefits of MPH on reaction time variability (Test of Variables of Attention mean score (SD) = 87.4 (26.7) with MPH vs. 63.2 (21.9) with PB, P < 0.0001).
Visual attention and task-switching
An open-label trial of children with ADHD + RD by Dykman et al. 44 documented improvements with MPH on visual task-switching (Trail Making Test-Trails B, effect size (ES) = 0.29, P < 0.001) but not visual attention (Trail Making Test-Trails A, P > 0.05).
Visual processing speed and sustained attention
Two open-label studies of children with ADHD + RD have assessed effects of MPH on visual processing speed (using the Weschler Intelligence Scale for Children-Revised Coding subtest), and both found beneficial effects. Keulers et al. 48 documented large beneficial effects of MPH on visual processing speed (η p 2 = 0.52, 53 (2017) (see Table 5 ) 2b b ADHD, attention-deficit/hyperactivity disorder; ATX, atomoxetine; CCT, controlled clinical trial; DBPC, Double-blind placebo-controlled; HI, hyperactivity/ impulsivity; IA, inattention; IQ, intelligence quotient; K-TEA, Kaufman Test of Educational Achievement; LD, learning disorder; RD, reading disorder; SS, standard score; WJIII, Woodcock Johnson III Tests of Achievement. a Described as randomized by authors but classified as a CCT rather than a randomized control trial due to lack of detail regarding randomization procedures.
b Quality rating downgraded from 1b due to <80% of participants completing study or failure to report the number of study dropouts.
c Naturalistic, open-label study, with premeasures and postmeasures.
P < 0.001), as did Dykman et al. 44 (ES = 1.06, P < 0.001). Keulers et al. 48 also found large significant effects of MPH on a sustained visual attention cancellation task in children with ADHD + RD (η p 2 = 0.56, P < 0.001 for attention accuracy and η p 2 = 0.43, P < 0.001 for attention speed on the Bourdon-Vos Test).
Visual-spatial working memory
In a DBPC trial of ADHD + LD (RD and/or MD), Williamson et al. 40 reported benefits of MPH on visual-spatial working memory using the Wide Range Assessment of Memory and Learning task (Finger Windows Forwards mean score (SD) = 12.8 (4.3) with MPH vs. 11.0 (3.2) with PB, P = 0.002; Finger Windows Backwards mean score (SD) = 9.7 (3.6) with MPH vs. 8.6 (4.3) with PB, P = 0.02).
Additional neuropsychological constructs
In a small sample of children with ADHD + RD (N = 25), Bental 45 did not observe improvements in short-term visual memory (assessed via Sprague and Sleator's Short-term Memory task) with MPH in ADHD + RD. 45 
Summary of findings
The few available publications on children with ADHD + RD assessing effects of stimulant medications on neuropsychological functioning suggest that MPH may have benefits on pairedassociate learning, rapid automatized naming skills, reaction time variability, sustained attention, visual processing speed, visual-spatial working memory, and visual task-switching, but more studies are needed to confirm these results. b Described as randomized by authors but classified as a CCT rather than a randomized control trial due to lack of detail regarding randomization procedures.
c Quality rating downgraded from 1b due to <80% of participants completing study.
ATOMOXETINE EFFECTS ON ADHD SYMPTOMS IN CHILDREN WITH ADHD + RD
We identified three independent samples investigating atomoxetine effects on ADHD symptoms in children with ADHD + RD, two of which were examined in DBPC trials 49, 50 and one which was examined in cohort analytic openlabel studies. 51, 52 Parent-reported ADHD symptoms Effects of atomoxetine on parent-reported ADHD symptoms in children with ADHD + RD were assessed in three samples. [49] [50] [51] [52] All studies reported significant improvements in parent ratings of ADHD symptoms. Medium to large ESs were observed in the DBPC trials, and large ESs were seen in the open-label trials. Specifically, in the DBPC crossover trial by de Jong et al., 49 parent-reported ADHD symptoms diminished after taking atomoxetine in children with ADHD + RD (medium to large ES of η p 2 = 0.23, P = 0.01). In a DBPC trial by Wietecha et al., 50 atomoxetine led to significantly greater improvement than PB in parent ratings of inattentive, hyperactive-impulsive, and ADHD total symptom scores (P values = 0.02-0.002, d = −0.40 to −0.53). In an open-label Described as randomized by authors but classified as a CCT rather than a randomized control trial due to lack of detail regarding randomization procedures.
c Quality rating downgraded from 1b due to failure to report number of study dropouts.
cohort reported on by both Sumner et al. 52 and Shaywitz et al. (2014) , 51 for the ADHD + RD group, improvements with atomoxetine were seen in parent-reported inattentive, hyperactive-impulsive, and ADHD total symptom scores (all P values < 0.001), with improvement ES ranging from d = 1.12-2.27 (mean change from baseline to end point in inattentive, hyperactive-impulsive, and total symptom scores was −10.5, −7.7, and −17.7, respectively).
Teacher-reported ADHD symptoms
We identified only one study evaluating the effects of atomoxetine on teacher ratings of ADHD symptoms in ADHD + RD. In a DBPC trial by Wietecha et al., 50 atomoxetine led to significantly greater improvement than PB in teacher ratings of ADHD inattentive symptom scores (P = 0.02, d = −0.68) for children with coexisting RD, but there was no significant atomoxetinerelated improvements in teacher-reported hyperactive-impulsive or ADHD total symptom scores.
Summary of findings
In children with ADHD + RD, atomoxetine had significant beneficial effects on parent ratings of inattentive and hyperactiveimpulsive symptoms in three independent samples, with larger effect sizes seen in open-label than in placebo-controlled trials. Significant effects of atomoxetine on teacher ratings of inattention but not hyperactivity-impulsivity were also observed in the single study that evaluated this outcome.
ATOMOXETINE EFFECTS ON ACADEMIC OUTCOMES IN CHILDREN WITH ADHD + RD
We found three independent trials (two DBPC and one cohort analytic open-label trial) 49, [51] [52] [53] in which academic outcomes of atomoxetine treatment in ADHD + RD were evaluated. Each of the three trials evaluating effects of atomoxetine on specific academic outcomes focused on reading-related outcomes, with none reporting effects on additional outcomes, such as mathematics.
Reading
Effects of atomoxetine on reading in children with ADHD + RD were evaluated in two DBPC 49, 53 and one open-label 51, 52 trial. In their DBPC crossover trial of children with ADHD + RD, de Jong et al. 49 did not observe significant improvements in lexical decision making (distinguishing real words and pseudowords) with atomoxetine. In the DBPC trial by Shaywitz et al. 53 (2017) children with ADHD + RD did have significantly greater improvement in elision skills (the ability to remove phonological segments from spoken words to form other words) on the Comprehensive Test of Phonological Processing (CTOPP) with atomoxetine compared to PB (P < 0.02, d = 0.50). However, this study did not find significant effects of atomoxetine on any of their eight other CTOPP outcomes, seven Woodcock Johnson III reading-related outcomes (including both reading decoding and reading comprehension measures), five Gray Oral Reading Test-4 outcomes, and three Test of Word Reading Efficiency outcomes. In contrast, in their open-label studies evaluating the same cohort of children with ADHD + RD, Shaywitz et al. 
Spelling
The effect of atomoxetine on spelling in children with ADHD + RD was evaluated in one DBPC 53 and one open-label trial. Significant improvements in spelling with atomoxetine were not seen in either study.
52,53
Summary of findings
There is little to no evidence regarding beneficial effects of atomoxetine on reading outcomes in children with ADHD + RD in DBPC studies, although significant improvements in reading decoding and comprehension with atomoxetine were seen in an open-label trial. Neither of the two studies assessing atomoxetine effects on spelling found significant beneficial effects.
ATOMOXETINE EFFECTS ON NEUROPSYCHOLOGICAL OUTCOMES IN CHILDREN WITH ADHD + RD
Three trials (two DBPC 49, 50 and one open-label 51,52 trial) investigating effects of atomoxetine on neuropsychological outcomes in children with ADHD + RD were identified. The neuropsychological constructs evaluated included response inhibition, verbal working memory, and visual-spatial working memory.
Response inhibition
One study evaluated atomoxetine effects on response inhibition in children with ADHD + RD. In a DBPC crossover trial by de Jong et al., 49 borderline significant effects (P = 0.07) of atomoxetine on response inhibition were observed for the ADHD + RD group, with faster reaction times on the Stop Signal Paradigm seen while on atomoxetine vs. PB.
Verbal working memory
One DBPC 50 and one open-label trial 51 50 did not. These studies also documented conflicting results on the WMTB-C Central Executive Working Memory domain (based on the Listening Recall, Counting Recall, and Backwards Digit Recall subtests): the DBPC trial 50 found that atomoxetine led to significantly greater improvement compared to PB (P = 0.01, d = 0.68), whereas the open-label trial did not observe significant effects of atomoxetine on this domain. 51, 52 Visual-spatial working memory Two DBPC 49, 50 trials and one open-label trial 51, 52 evaluated the effects of atomoxetine on verbal working memory in ADHD + RD. In their DBPC crossover trial, de Jong et al. 49 found that visualspatial working memory (assessed on the Corsi Block Tapping Test) improved with atomoxetine compared to PB (ES medium to large as η p 2 = 0.13, P = 0.01) in children with ADHD + RD. However, in another DBPC trial 50 as well as an open-label trial 51, 52 in children with ADHD + RD, atomoxetine did not improve visual-spatial working memory (assessed using the WMTB-C Visuospatial Sketchpad score, which is based on Block Recall and Mazes Memory subtests).
Summary of findings
Effects of atomoxetine on verbal and visual-spatial working memory were mixed in studies of children with ADHD + RD. The single study assessing atomoxetine effects on response inhibition in ADHD + RD found borderline significant beneficial effects.
OVERALL STRENGTH OF EVIDENCE
The limited body of evidence suggests that treatment with ADHD medication can be associated with some improvements in ADHD symptoms, select academic outcomes, and specific neuropsychological impairments in children with coexisting ADHD and RD. Medication effects were generally more robust for ADHD symptoms than for academic or neuropsychological outcomes. We found largely consistent evidence that these two medications can improve ADHD symptoms in coexisting ADHD and RD, with the quality of the available studies rated as moderate to strong for MPH (Oxford Centre for Evidence-Based Medicine 39 level 2b for four studies and level 1b for two studies) and as moderate for atomoxetine (Oxford level 2b for three trials). Notably, the evidence for atomoxetine rests primarily on studies of parent-reported symptom ratings, with only one trial documenting beneficial effects on teacher symptom ratings, whereas beneficial effects of MPH were observed on teacher symptom ratings in five studies and on blinded direct behavior observations in one study. In the case of academic outcomes, there was consistent evidence across the few available studies that MPH can improve math computation performance in children with ADHD + RD, with the quality of available studies generally rated as moderate (Oxford level of 2b for three studies). On the other hand, we found weak evidence for improvement in reading outcomes with MPH (inconsistent findings across studies) and atomoxetine (inconsistent findings across studies) in this group. There is emerging evidence that MPH can improve performance on select neuropsychological measures in children with ADHD + RD, but the quality of evidence is considered to be weak at this time due to the identification of only 1-2 studies investigating each domain. We did not find evidence suggesting improvement in neuropsychological test performance with atomoxetine in the few available ADHD + RD trials (inconsistent or negative findings).
LIMITATIONS OF THE AVAILABLE EVIDENCE
As noted by the tempered strength of evidence ratings, these findings should be interpreted with caution given the sparsity of the available literature and its numerous limitations. We endeavored to capture these limitations systematically by abstracting data from each study using the EPHPP Quality Assessment Tool. 36 The "Comments" columns in Tables 1-6 highlight notable sources of bias in individual studies. Special attention should be paid to patterns of weakness across studies. For example, among the nine studies assessing stimulant effects in ADHD + LD, three excluded children with a history of stimulant intolerance or poor response, [40] [41] [42] thus likely overestimating the beneficial effects of MPH. The predominance of white participants (or a lack of reporting of participants' racial backgrounds) also constrains generalizability of the MPH study findings. In addition, all of the trials evaluating atomoxetine effects in ADHD + RD were funded by and study authors had affiliations with Eli Lilly and Company (Indianapolis, IN), the manufacturer of Strattera (atomoxetine branded formulation), which may represent a perceived conflict of interest. However, given that public agencies often lack the capacity to fund studies needed to further the understanding of medication effects, it should be noted that studies sponsored by pharmaceutical companies can fill this important gap and thereby help to improve clinical care. There is also a risk that reported atomoxetine effects are inflated given the degree of attrition (<80% completed the trial) 50, 53 or failure to report level of dropout 49 in the DBPC studies, as poor response is a primary reason for withdrawal from medication trials. By and large, both MPH and atomoxetine studies were also of relatively short duration, with only the stimulant trial by Hechtman et al. 46 assessing medication treatment longer than 1 year (e.g., 14 months), whereas a longer observation period is likely needed to capture changes in academic skills that accrue over time. The extreme heterogeneity of the academic and neuropsychological measures used also makes it difficult to draw conclusions across studies. Even when common measures were used across studies, differences in analytic methods and inconsistent reporting of effect sizes hamper efforts to compare or pool findings.
MEDICATION EFFECTS ON ADHD SYMPTOMS IN ADHD + RD VS. ADHD ONLY
Despite these limitations, the available literature can help clinicians and families to understand the benefits that medication may confer upon children with ADHD + RD, and how this may compare to what is seen in children with ADHD only. The body of evidence does suggest that, as with ADHD only, MPH and atomoxetine can effectively reduce ADHD symptoms in children with ADHD + RD. However, whether MPH response rates and effect sizes are similar in ADHD + RD and uncomplicated ADHD is not completely clear. The MPH response rates in ADHD + RD were similar to what is observed in more general pediatric ADHD samples (77%) 54, 55 in studies by Williamson et al. 40 (79%) and Grizenko et al. 41 (67%), whereas the atomoxetine studies did not assess response rates. The observed magnitudes of effect in the studies reviewed were not consistently equivalent to the large effect size seen for MPH (d = 1.0) and the medium to large effect size seen for atomoxetine (d = 0.63) 56 in children with uncomplicated ADHD. Effect sizes were varied in the few DBPC trials assessing impact of MPH on core ADHD symptoms in ADHD + RD: one trial observed large ESs for reductions in teacher-reported and parent-reported ADHD symptoms at the highest administered MPH dose (0.7 mg/kg) 45 and another found improvements of large ES for direct observations of attention and deportment, 40 whereas a third found only modestly size MPH-related improvements in teacher hyperactivity-impulsivity ratings and no significant effects on teacher-rated and parent-rated inattention or parent-rated hyperactivity-impulsivity in intent-to-treat analyses. 42 In the two DBPC trials assessing atomoxetine's impact on ADHD symptoms in ADHD + RD, one trial found medium 50 and another found medium to large 49 ESs for parent ratings of ADHD symptoms, whereas the single trial assessing impact on teacher symptom ratings found medium to large ESs for inattention and no significant effects for hyperactivity-impulsivity. 50 
MEDICATION EFFECTS ON ACADEMIC OUTCOMES IN ADHD + RD VS. ADHD ONLY
Our review of studies focused on children with coexisting ADHD + RD found mixed MPH effects on reading measures, consistent beneficial MPH effects on math outcomes, and little evidence for beneficial atomoxetine effects on reading outcomes. The MPH math-related findings in ADHD + RD samples are consistent with findings in ADHD-only samples, for which a recent meta-analysis documented beneficial effects of MPH on math productivity and accuracy. 30 We are unable to find a point of comparison for the MPH mixed effects on phonological processing outcomes in ADHD + RD samples due to the paucity of prior research on these outcomes in children with uncomplicated ADHD. Our review found little evidence regarding medication effects on long-term academic outcomes in children with ADHD + RD other than a borderline significant reduced likelihood of participants maintaining their RD status after 14 months of stimulant medication treatment in the Multimodal Treatment Assessment trial. 48 Intriguingly, some prior research focused on academic functioning in ADHD-only samples over the years have shown that youths who take stimulant medication may have some improvements in standardized academic achievement test scores. [57] [58] [59] [60] However, all of the long-term studies in uncomplicated ADHD samples are limited by their lack of control for some important potential confounding variables. Unlike MPH, there has been little prior study of either short-term or long-term atomoxetine effects on standardized academic achievement test outcomes in uncomplicated ADHD samples, 23, 61, 62 so it is not possible to provide further contextualization of the findings in ADHD + RD samples.
MEDICATION EFFECTS ON NEUROPSYCHOLOGICAL OUTCOMES IN ADHD + RD VS. ADHD ONLY
Neuropsychological test performance has long been of interest as a marker for how medications may scaffold brain functioning in children diagnosed with ADHD, although the association between performance on neuropsychological tests and real-world academic and behavioral functioning is limited. [63] [64] [65] Given the compounded difficulties experienced by children with coexisting ADHD + RD, clinicians and families are eager to understand the potential of ADHD medications to ameliorate execution dysfunction in this group. As has been observed in many but not all studies of children with uncomplicated ADHD, 54, [66] [67] [68] [69] the few available studies of medication effects on neuropsychological functioning in ADHD + RD provide some evidence that MPH may improve rapid automatized naming, sustained attention, reaction time variability, and paired associate learning, as well as visual-spatial working memory, processing speed, and task-switching. Methylphenidate-related improvements in certain neuropsychological domains may be particularly salient for improving academic functioning in children with ADHD + RD. For example, rapid automatized naming deficiencies, weaknesses in sustained attention, slow processing speed, and working memory deficits have all been implicated in RD. 17, 70, 71 Compared to MPH, improvements in executive functioning in ADHD + RD do not seem to be as robust with atomoxetine. Although studies in ADHD-only samples show an emerging pattern that atomoxetine may improve working memory [72] [73] [74] [75] and response inhibition, 72, 76, 77 the available literature in ADHD + RD did not provide convincing documentation of atomoxetine's beneficial effects on these domains, as effects were either mixed or borderline significant.
FUTURE DIRECTIONS
Collectively, the studies included in this review provide some insights into the potential for medication treatment to improve both core ADHD symptoms as well as specific skills related to academic achievement in reading and math in children with ADHD + RD. Nevertheless, future research is required to address challenges with the existing literature, as well as broader questions about the relationship between attention and LDs, and the extent to which treatment can ameliorate academic underachievement in children with coexisting ADHD + RDs. Future intervention studies investigating treatment effects in ADHD + RD should enroll children who are treatment naïve, or who are enrolled without knowledge of prior treatment response, to avoid biases that may arise by excluding children with a history of poor response to a specific medication. Similarly, additional intervention studies should focus on children who have ADHD along with the same, well-defined deficit (e.g., impaired phonological awareness) rather than a heterogeneous array of different deficits related to reading, so that the precise impact of medication can be evaluated. The studies cited in this review demonstrate that medication may differentially impact academic performance in the various domains (e.g., reading vs. math). This presumably reflects the differing extent to which attention concentration and the various executive functions are directly related to the task. For example, the most consistent finding related to medication treatment and academic functioning in uncomplicated ADHD samples is improvement in speed of completing schoolwork. Work speed may be more related to performance of some academic tasks (e.g., math computation worksheets) than others (e.g., demonstrating reading comprehension through expository writing). Determining the extent to which medication may improve the academic performance of children with ADHD + RD beyond improving speed and demonstration of rote skills is critically needed. In particular, written expression is an important area for future investigation: some studies suggest it is the most challenging academic domain for children with ADHD, as it depends heavily on organization and initiation as well as attention and concentration. Furthermore, because many children with ADHD have academic impairment in multiple academic domains, treatment response for various combinations of learning problems should be characterized. Future studies should also expand beyond investigation of MPH and atomoxetine effects in ADHD + RD to investigate the impact of amphetamine-based, guanfacine-based, and clonidine-based preparations.
Moreover, because medication may impact academic functioning by improving learning in response to instruction and practice over time, long-term treatment studies in children with ADHD + RD are needed. Study duration must be sufficient to permit assessment of changes in specific academic skills, which are unlikely to change significantly in weeks or even months. It will also be important to conduct studies that combine ADHD medication treatment with evidence-based educational interventions for specific learning difficulties, such as phonologically based reading instruction. Ultimately, improving care for children with coexisting ADHD + RD will require clinical effectiveness studies that evaluate long-term academic achievement as a function of baseline ADHD/RD status, as well as medication treatment and educational interventions received over time. 
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